Although the clinical benefit of the AMPK activation-mediated targeted therapy with a combined cocktail of lipid metabolic modulators is still reticently reported, the innovative idea proposed herein may recommend the feasibility of this alternative therapeutic intervention to impede ovarian cancer peritoneal metastases. Here, PRKAA1 is linked to ovarian cancer.